Bottom line
XLV vs FACDX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and FACDX (Fidelity Advisor Health Care Fund) share a meaningful slice of their top holdings — about 45% by weight.
But FACDX is far broader, holding 154 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 0.96% — a difference of $88 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +2.3% for FACDX (reporting dates differ).
Updated Nov 19, 2026
XLV vs FACDX side by side
| XLV | FACDX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.96% |
| Annual cost per $10k | $8 | $96 |
| 10-yr cost on $10k (prospectus) | $103 | $1,685 |
| Max front load | None | — |
| 12b-1 fee | 0.02% | 0.25% |
| 1-yr return | +14.5% | +7.7% |
| 5-yr return (annualized) | +8.1% | +2.3% |
| 10-yr return (annualized) | +9.8% | +7.6% |
| Best quarter | +14.5% | +21.3% |
| Worst quarter | −12.7% | −15.0% |
| Net assets (fund) | $40.6B | $3.1B |
| Number of holdings | 65 | 154 |
| Portfolio turnover | 2% | 74% |
| Returns as of | Dec 31, 2025 | Sep 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | FACDX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +14.2% | +0.3% |
| 2024 | +2.5% | +3.9% | −1.4% |
| 2023 | +2.0% | +3.8% | −1.8% |
| 2022 | −2.1% | −13.1% | +11.0% |
| 2021 | +25.9% | +11.2% | +14.7% |
| 2020 | +13.3% | +21.1% | −7.8% |
| 2019 | +20.7% | +27.9% | −7.2% |
| 2018 | +6.3% | +7.3% | −1.1% |
| 2017 | +21.7% | +24.1% | −2.4% |
| 2016 | −2.8% | −10.3% | +7.5% |
Source: Fund prospectus bar charts
Holdings overlap
10 of XLV's top 25 holdings also appear in FACDX's top 25.
| Holding | XLV | FACDX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 7.66% |
| Johnson & Johnson | 10.64% | 3.78% |
| AbbVie Inc | 7.74% | 3.62% |
| UnitedHealth Group Inc | 6.57% | 4.17% |
| Merck & Co Inc | 5.52% | 2.09% |
| Thermo Fisher Scientific Inc | 3.24% | 6.31% |
| Gilead Sciences Inc | 2.73% | 1.25% |
| CVS Health Corp | 2.30% | 1.29% |
| Danaher Corp | 2.09% | 6.75% |
| Boston Scientific Corp | 1.10% | 1.23% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FACDX top 10
- ELI LILLY and CO — 7.66%
- Danaher Corp — 6.75%
- Thermo Fisher Scientific Inc — 6.31%
- Unitedhealth Group Inc — 4.17%
- JOHNSON and JOHNSON — 3.78%
- Abbvie Inc — 3.62%
- Fidelity Revere Street Trust — 2.54%
- Argenx Se — 2.09%
- MERCK and CO INC — 2.09%
- West Pharmaceutical Svcs Inc — 2.06%
FAQ
What is the difference between XLV and FACDX?
Which is cheaper, XLV or FACDX?
Should I own both XLV and FACDX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.